NMS · Biotechnology

4D Molecular Therapeutics, Inc. (FDMT) Stock

$13.31 +4.80% NMS: FDMT Healthcare

Valuation

MetricValue
Price$13.31
Market Cap$695.80M
P/E Ratio-5.03
P/B Ratio2.36
P/S Ratio7.77
EPS (TTM)$-2.42
52-Week High$16.93
52-Week Low$6.96
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-41.33%
ROA-36.37%
ROCE-44.30%
Gross Margin-188.24%
Operating Margin-188.24%
Net Margin-194.74%
Debt/Equity0.10
Current Ratio9.39

Annual Financials (USD)

Metric20212022202320242025
Revenue$18.0M$3.0M$21.0M$0$85.0M
Operating Profit$-71.0M$-110.0M$-113.0M$-188.0M$-160.0M
Net Profit$-71.0M$-107.0M$-101.0M$-161.0M$-140.0M
EPS$-2.46$-3.12$-2.58$-2.98$-2.42
Op Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$353.0M$262.0M$340.0M$560.0M$567.0M
Total Liabilities$34.0M$31.0M$32.0M$50.0M$61.0M
Cash$153.0M$52.0M$249.0M$149.0M$60.0M
Borrowings$16.0M$16.0M$15.0M$25.0M$21.0M

Latest News

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists GlobeNewswire · Jun 30, 2026 4D Molecular Therapeutics Completes Enrollment in Phase 3 Wet AMD Trial MT Newswires · Jun 29, 2026 4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD GlobeNewswire · Jun 29, 2026 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital GlobeNewswire · Jun 29, 2026 Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-69.0M$-87.0M$-76.0M$-135.0M$-109.0M
Investing Cash Flow$-182.0M$-29.0M$113.0M$-306.0M$-94.0M
Financing Cash Flow$4.0M$0$0$6.0M$0
Net Cash Flow$-124.0M$-101.0M$197.0M$-100.0M$-89.0M
Free Cash Flow$-78.0M$-98.0M$-79.0M$-138.0M$-109.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.34
EV / EBITDA-3.70
FCF Yield-21.92%
Quick Ratio8.03
Interest Coverage0.00
Return 1Y120.38%
Return 3Y-43.19%
Return 5Y-49.81%

Ownership

Insiders Held3.32%
Institutions Held98.36%
Institutions Float Held101.74%
Institutional HolderSharesReport Date
Janus Henderson Group PLC5,247,1512026-03-31
RA Capital Management, L.P.5,049,7792026-03-31
Goldman Sachs Group Inc4,205,4382026-03-31
Blackrock Inc.4,145,3032026-03-31
Novo Holdings A/S3,650,7372026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $337.01 -1.00% 38.93 $4.95T 0.32%
MSFTMicrosoft Corporation $535.56 +2.48% 28.68 $3.98T 0.76%
GOOGLAlphabet Inc. $351.83 +1.01% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.58 +3.35% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $719.34 -0.22% 27.93 $1.83T 0.28%

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is led by CEO David H. Kirn, employs 227 people, headquartered in US, publicly traded since 2020.

4D Molecular Therapeutics, Inc. (FDMT) stock trades at $13.31 with a market capitalization of $695.80M. The stock is valued at a price-to-earnings (P/E) ratio of -5.03, price-to-book of 2.36, price-to-sales of 7.77. Over the past 52 weeks the stock has ranged between $6.96 and $16.93, and currently trades 21.4% below its 52-week high.

On profitability, 4D Molecular Therapeutics, Inc. generates a return on equity (ROE) of -41.33%, return on capital employed of -44.30%, an operating margin of -188.24%, a net profit margin of -194.74%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1175.87 +0.54% JNJ Johnson & Johnson $260.78 +1.68% ABBV AbbVie Inc. $276.48 +1.49% MRK Merck & Company, Inc. Common Stock (new) $146.30 +2.75% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.88 +2.41% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.57 +0.86% AMGN Amgen Inc. $415.91 +2.08% GILD Gilead Sciences, Inc. $150.59 +2.37% ABT Abbott Laboratories $99.58 +1.10% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides